959909-79-6

Basic information

• Product Name: 4-(1-methyl-1H-pyrazol-4-yl)-2-nitrobenzenamine
• Synonyms: 4-(1-methyl-1H-pyrazol-4-yl)-2-nitrobenzenamine
• CAS NO: 959909-79-6
• Molecular Weight: 218.215
• Mol File: 959909-79-6.mol
• Article Data: 9

Chemical Properties

• CAS DataBase Reference: 4-(1-methyl-1H-pyrazol-4-yl)-2-nitrobenzenamine(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(1-methyl-1H-pyrazol-4-yl)-2-nitrobenzenamine(959909-79-6)
• EPA Substance Registry System: 4-(1-methyl-1H-pyrazol-4-yl)-2-nitrobenzenamine(959909-79-6)

Safety Data

• Hazardous Substances Data: 959909-79-6(Hazardous Substances Data)

Upstream product

• 875-51-4 4-Bromo-2-nitroaniline 
• 847818-55-7 (1-methyl-1H-pyrazol-4-yl)boronic acid 
• 1228392-59-3 N-(4-bromo-2-nitrophenyl)-N-tert-butoxycarbonylcarbamic acid tert-butyl ester 
• 761446-44-0 1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole 

Downstream Products

• 959909-80-9 4-(4-iodo-3-nitro-phenyl)-1-methyl-1H-pyrazol 

Relevant articles and documents

Fused tricyclic derivative as FGFR4 inhibitor

The present invention provides a fused tricyclic derivative that is the selective inhibitor of fibroblast growth factor receptor 4 (FGFR4), a pharmaceutical composition containing the compound, a method of making the compound and a method of treating cell proliferative diseases, such as cancer, using the compounds of the invention.

Heterocycle type derivative and preparing method and pharmaceutical application thereof

The invention relates to a novel heterocycle type derivative, a preparing method thereof, a medicine composition containing the derivative and application of the heterocycle type derivative as therapeutic agent, particularly an FGFR4 inhibitor. The preferable compound has a good inhibiting effect on FGFR4.

PROTEIN KINASE INHIBITORS

A compound of formula (I), wherein R1 to R5, A, B, Z, Z1 and Z2 are as defined in the claims, and pharmaceutically acceptable salts thereof are disclosed. The compounds of formula (I) possess utility as FGFR inhibitors and are useful in the treatment of a condition, where FGFR kinase inhibition is desired, such as cancer.